Antisense antibiotics: A brief review of novel target discovery and delivery

Current Drug Discovery Technologies

Volumn 7, Issue 2, 2010, Pages 76-85

  Bai, Hui ^a   Xue, Xiaoyan ^a   Hou, Zheng ^a   Zhou, Ying ^a   Meng, Jingru ^a   Luo, Xiaoxing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antibiotic resistance; Antisense antibiotics; Antisense oligonucleotides

Indexed keywords

ANTIBIOTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA LACTAMASE INHIBITOR; CELL PENETRATING PEPTIDE; PROTON PUMP INHIBITOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL GENE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; GENE EXPRESSION; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 78649592900     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016310793180594     Document Type: Review

References (101)

1. Gootz TD. The global problem of antibiotic resistance. Crit Rev Immunol 2010; 30: 79-93.
2. Fernando GA, Collignon PJ, Bell JM. A risk for returned travellers: the "post-antibiotic era". Med J Aust 2010; 193: 59.
3. English BK, Gaur AH. The use and abuse of antibiotics and the development of antibiotic resistance. Adv Exp Med Biol 2010; 659: 73-82.
4. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8: 260-71.
5. Kerwat K, Kerwat M, Graf J, et al. Resistance to antibiotics and multiresistant pathogens. Anasthesiol Intensivmed Notfallmed Schmerzther 2010; 45: 242-43.
6. Ruef C. Antibiotic resistance-running out of treatment options. Infection 2007; 35: 1.
7. Lakovlev SV, Protsenko DN, Shakhova TV, et al. Antibiotic resistance in hospital: do we control the situation? Antibiot Khimioter 2010; 55: 50-58.
8. Petrosillo N, Capone A, Di Bella S, et al. Management of antibiotic resistance in the intensive care unit setting. Expert Rev Anti Infect Ther 2010; 8: 289-302.
9. Allen HK, Donato J, Wang HH, et al. Call of the wild: antibiotic resistance genes in natural environments. Nat Rev Microbiol 2010; 8: 251-59.
10. Pournaras S, Iosifidis E, Roilides E. Advances in antibacterial therapy against emerging bacterial pathogens. Semin Hematol 2009; 46: 198-211.
11. Cattoir V, Daurel C. Update on antimicrobial chemotherapy. Med Mal Infect 2010; 40: 135-54.
12. Nathwani D. Health economic issues in the treatment of drugresistant serious Gram-positive infections. J Infect 2009; 59( Suppl 1): S40-50.
13. Furtado GH, Perdiz LB, Santana IL, et al. Impact of a hospitalwide antimicrobial formulary intervention on the incidence of multidrug-resistant gram-negative bacteria. Am J Infect Control 2008; 36: 661-64.
14. Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010; 340: c2096.
15. Peleg AY, Hooper DC. Hospital-acquired infections due to gramnegative bacteria. N Engl J Med 2010; 362: 1804-13.
16. Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009; 12: 476-81.
17. Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycinintermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.
18. Pitout JD. Infections with extended-spectrum beta-lactamaseproducing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010; 70: 313-33.
19. Tsioutis C, Kritsotakis EI, Maraki S, et al. Infections by pandrugresistant gram-negative bacteria: clinical profile,therapeutic management, and outcome in a series of 21 patients. Eur J Clin Microbiol Infect Dis 2010; 29: 301-305.
20. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7: 629-41.
21. Parwati I, van Crevel R, van Soolingen D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis 2010; 10: 103-11.
22. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602.
23. Jagusztyn-Krynicka EK, Wyszyńska A. The decline of antibiotic era-new approaches for antibacterial drug discovery. Pol J Microbiol 2008; 57: 91-98.
24. Wright GD, Sutherland AD. New strategies for combating multidrug-resistant bacteria. Trends Mol Med 2007; 13: 260-67.
25. Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science 2009; 325: 161-65.
26. MacLean RC, Hall AR, Perron GG, et al. The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nat Rev Genet 2010; 11: 405-14.
27. Baron C. Antivirulence drugs to target bacterial secretion systems. Curr Opin Microbiol 2010; 13: 100-105.
28. Alksne LE, Dunman PM. Target-based antimicrobial drug discovery. Methods Mol Biol 2008; 431: 271-83.
29. Pucci MJ. Novel genetic techniques and approaches in the microbial genomics era: identification and/or validation of targets for the discovery of new antibacterial agents. Drugs 2007; 8: 201-12.
30. Wright GD. Making sense of antisense in antibiotic drug discovery. Cell Host Microbe 2009; 6: 197-98.
31. Costerton WJ, Montanaro L, Balaban N, et al. Prospecting gene therapy of implant infections. Int J Artif Organs 2009; 32: 689-95.
32. Wiersinga WJ. Beyond antibiotics: new horizons in treating burkholderia species infections. J Infect Dis 2010; 201: 1786-87.
33. Zamecnik P. Background of the antisense oligonucleotide approach to chemotherapy. Antisense Nucleic Acid Drug Dev 1997; 7: 199-202.
34. Woodford N, Wareham DW. Tackling antibiotic resistance: a dose of common antisense? J Antimicrob Chemother 2009; 63: 225-29.
35. Rasmussen LC, Sperling-Petersen HU, Mortensen KU. Hitting bacteria at the heart of the central dogma: sequence-specific inhibition. Microb Cell Factories 2007; 6: 24.
36. Houseley J, Tollervey D. The many pathways of RNA degradation. Cell 2009; 136: 763-76.
37. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-93.
38. Kurreck J. Antisense technologies Improvement through novel chemical modifications. Eur J Biochem 2003; 270: 1628-44.
39. Almeida J, Westhof E. The dynamic landscapes of RNA architecture. Cell 2009; 136: 604-609.
40. Vickers TA, Wyatt JR, Burckin T, et al. Fully modified 2'-MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res 2001; 29: 1293-99.
41. Sazani P, Gemignani F, Kang SH, et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol 2002; 20: 1228-33.
42. Roberts J, Palma E, Sazani P, et al. Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther 2006; 14: 471-5.
43. Vickers TA, Zhang H, Graham MJ, et al. Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2'-O-methoxyethylmodified oligonucleotide. J Immunol 2006; 176: 3652-61.
44. Nielsen PE. Peptide nucleic acids as antibacterial agents via the antisense principle. Expert Opin Investig Drugs 2001; 10: 331-41.
45. Rahman MA, Summerton J, Foster E, et al. Antibacterial activity and inhibition of protein synthesis in Escherichia coli by antisense DNA analogs. Antisense Res Dev 1991; 1: 319-27.
46. Kramer R, Cohen D. Functional genomics to new drug targets. Nat Rev Drug Discov 2004; 3: 965-72.
47. Greenberg DE, Marshall-Batty KR, Brinster LR, et al. Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J Infect Dis 2010; 201: 1822-30.
48. Mellbye BL, Weller DD, Hassinger JN, et al. Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of Escherichia coli in vitro and in vivo. J Antimicrob Chemother 2010; 65: 98-106.
49. Mitev GM, Mellbye BL, Iversen PL, et al. Inhibition of intracellular growth of Salmonella enterica serovar Typhimurium in tissue culture by antisense peptide-phosphorodiamidate morpholino oligomer. Antimicrob Agents Chemother 2009; 53: 3700-704.
50. Mellbye BL, Puckett SE, Tilley LD, et al. Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo. Antimicrob Agents Chemother 2009; 53: 525-30.
51. Nikravesh A, Dryselius R, Faridani OR, et al. Antisense PNA accumulates in Escherichia coli and mediates a long post-antibiotic effect. Mol Ther 2007; 15: 1537-42.
52. Tan XX, Actor JK, Chen Y. Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection. Antimicrob Agents Chemother 2005; 49: 3203-207.
53. Good L, Awasthi SK, Dryselius R, et al. Bactericidal antisense effects of peptide-PNA conjugates. Nat Biotechnol 2001; 19: 360-64.
54. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010; 23: 160-201.
55. Stavri M, Piddock L, Gibbons S. Bacterial efflux pump inhibitors from natural sources. J Antimicrob Chemother 2007; 59: 1247-60.
56. Livermore DM, Mushtaq S, Warner M, et al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β- lactamases and carbapenemases. J Antimicrob Chemother 2008; 62: 1053-56.
57. White DG, Maneewannakul K, von Hofe E, et al. Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs. Antimicrob Agents Chemother 1997; 41: 2699-704.
58. Soler Bistué AJ, Ha H, Sarno R, et al. External guide sequences targeting the aac(6')-Ib mRNA induce inhibition of amikacin resistance. Antimicrob Agents Chemother 2007; 51: 1918-25.
59. Sarno R, Ha H, Weinsetel N, et al. Inhibition of aminoglycoside 6'- N-acetyltransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides. Antimicrob Agents Chemother 2003; 47: 3296-304.
60. Chen H, Ferbeyre G, Cedergren R. Efficient hammerhead ribozyme and antisense RNA targeting in a slow ribosome Escherichia coli mutant. Nat Biotechnol 1997; 15: 432-35.
61. Gao MY, Xu CR, Chen R, et al. Chloromycetin resistance of clinically isolated E. coli is conversed by using EGS technique to repress the chloromycetin acetyl transferase. World J Gastroenterol 2005; 11: 7368-73.
62. Torres Viera C, Tsiodras S, Gold HS, et al. Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer. Antimicrob Agents Chemother 2001; 45: 973-75.
63. Jeon B, Zhang Q. Sensitization of Campylobacter jejuni to fluoroquinolone and macrolide antibiotics by antisense inhibition of the CmeABC multidrug efflux transporter. J Antimicrob Chemother 2009; 63: 946-48.
64. Meng J, Wang H, Hou Z, et al. Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillinresistant Staphylococcus aureus and rescues mice from lethal sepsis by targeting mecA. Antimicrob Agents Chemother 2009; 53: 2871-78.
65. Kedar GC, Brown-Driver V, Reyes DR, et al. Evaluation of the metS and murB loci for antibiotic discovery using targeted antisense RNA expression analysis in Bacillus anthracis. Antimicrob Agents Chemother 2007; 5: 1708-18.
66. Harth G, Zamecnik PC, Tabatadze D, et al. Hairpin extensions enhance the efficacy of mycolyl transferase-specific antisense oligonucleotides targeting Mycobacterium tuberculosis. Proc Natl Acad Sci 2007; 104: 7199-204.
67. Harth G, Horwitz MA, Tabatadze D, et al. Targeting the Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex as a therapeutic strategy against tuberculosis: Proof of principle by using antisense technology 2002; 99: 15614-19.
68. Harth G, Zamecnik PC, Tang JY, et al. Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/ glutamine cell wall structure, and bacterial replication. Proc Natl Acad Sci USA 2000; 97: 418-23.
69. Kurupati P, Tan KS, Kumarasinghe G, et al. Inhibition of gene expression and growth by antisense peptide nucleic acids in a multiresistant beta-lactamase-producing Klebsiella pneumoniae strain. Antimicrob Agents Chemother 2007; 51: 805-11.
70. Kulyté A, Nekhotiaeva N, Awasthi SK, et al. Inhibition of Mycobacterium smegmatis gene expression and growth using antisense peptide nucleic acids. J Mol Microbiol Biotechnol 2005; 9: 101-109.
71. Shimizu T, Sato K, Sano C, et al. Effects of antisense oligo DNA on the antimicrobial activity of reactive oxygen intermediates and antimycobacterial agents against Mycobacterium avium complex. Kekkaku 2003; 78: 33-35.
72. Stock RP, Olvera A, Sánchez R, et al. Inhibition of gene expression in Entamoeba histolytica with antisense peptide nucleic acid oligomers. Nat Biotechnol 2001; 19: 231-4.
73. Guo QY, Xiao G, Li R, et al. Treatment of Streptococcus mutans with antisense oligodeoxyribonucleotides to gtfB mRNA inhibits GtfB expression and function. FEMS Microbiol Lett 2006; 264: 8-14.
74. Nekhotiaeva N, Awasthi SK, Nielsen PE, et al. Inhibition of Staphylococcus aureus gene expression and growth using antisense peptide nucleic acids. Mol Ther 2004; 10: 652-59.
75. Ji Y, Yin D, Fox B, et al. Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. FEMS Microbiol Lett 2004; 231: 177-84.
76. Xue-Wen H, Jie P, Xian-Yuan A, et al. Inhibition of bacterial translation and growth by peptide nucleic acids targeted to domain II of 23S rRNA. J Pept Sci 2007; 13: 220-26.
77. Gruegelsiepe H, Brandt O, Hartmann RK. Antisense inhibition of RNase P: mechanistic aspects and application to live bacteria. J Biol Chem 2006; 281: 30613-20.
78. Good L, Nielsen PE. Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA. Proc Natl Acad Sci USA 1998; 95: 2073-76.
79. Good L, Nielsen PE. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat Biotechnol 1998; 16: 355-58.
80. Singh Y, Murat P, Defrancq E. Recent developments in oligonucleotide conjugation. Chem Soc Rev 2010; 39: 2054-70.
81. Shao Y, Wu Y, Chan CY, et al. Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation. Nucleic Acids Res 2006; 34: 5660-69.
82. Tauşer RG, Stoica O. Basic principles of the antisense strategy. Rev Med Chir Soc Med Nat Iasi 2003; 107: 483-86.
83. Ding Y, Lawrence CE. A statistical sampling algorithm for RNA secondary structure prediction. Nucleic Acids Res 2003; 31: 7280-301.
84. Hatamoto M, Ohashi A, Imachi H. Peptide nucleic acids (PNAs) antisense effect to bacterial growth and their application potentiality in biotechnology. Appl Microbiol Biotechnol 2010; 86: 397-402.
85. Good L, Sandberg R, Larsson O, et al. Antisense PNA effects in Escherichia coli are limited by the outer-membrane LPS layer. Microbiology 2000; 146 (Pt 10): 2665-70.
86. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs 2009; 69: 1555-623.
87. Garcia-Chaumont C, Seksek O, Grzybowska J, et al. Delivery systems for antisense oligonucleotides. Pharmacol Ther 2000; 87: 255-77.
88. Fenske DB, Cullis PR. Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol 2005; 391: 7-40.
89. Johnson JE, Chiu W. DNA packaging and delivery machines in tailed bacteriophages. Curr Opin Struct Biol 2007; 17: 237-43.
90. Lebleu B, Moulton HM, Abes R, et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 2008; 60: 517-29.
91. Henke E, Perk J, Vider J, et al. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol 2008; 26: 91-100.
92. Nekhotiaeva N, Elmquist A, Rajarao GK, et al. Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. FASEB J 2004; 18: 394-96.
93. Said Hassane F, Saleh AF, Abes R, et al. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci 2010; 67: 715-26.
94. Patel LN, Zaro JL, Shen WC. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res 2007; 24: 1977-92.
95. Chugh A, Eudes F, Shim YS. Cell-penetrating peptides: Nanocarrier for macromolecule delivery in living cells. IUBMB Life 2010; 62: 183-93.
96. Hatamoto M, Nakai K, Ohashi A, et al. Sequence-specific bacterial growth inhibition by peptide nucleic acid targeted to the mRNA binding site of 16S rRNA. Appl Microbiol Biotechnol 2009; 84: 1161-68.
97. Foerg C, Merkle HP. On the biomedical promise of cell penetrating peptides: limits versus prospects. J Pharm Sci 2008; 97: 144-62.
98. Mansoor M, Melendez AJ. Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul Syst Bio 2008; 2: 275-95.
99. Piper C, Cotter PD, Ross RP, et al. Discovery of medically significant lantibiotics. Curr Drug Discov Technol 2009; 6: 1-18.
100. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science 2009; 28; 325: 1089-93.
101. Cipolla L, Polissi A, Airoldi C, et al. The Kdo biosynthetic pathway toward OM biogenesis as target in antibacterial drug design and development. Curr Drug Discov Technol 2009; 6: 19-33.